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Abstract
Background: Excitotoxic brain insult is associated with extensive neuronal damage but could also cause
inflammatory reactivity and vascular remodeling. The effects of the vascular endothelial growth factor (VEGF)
inhibitor, Cyclo-VEGI on expression of VEGF, microgliosis and astrogliosis, blood-brain barrier (BBB) integrity
and neuronal viability have been studied following intra-striatal injection of the excitotoxin, quinolinic acid
(QUIN). The purpose of this study was to examine VEGF-dependent inflammatory responses in excitotoxin-
injected brain and their dependence on pharmacological antagonism of VEGF receptors.
Methods: Single and double immunofluorescence staining of cellular (microglia, astrocyte, neuron) responses and
dye and protein infiltration of blood-brain barrier have been applied in the absence, and presence, of
pharmacological modulation using a VEGF receptor antagonist, Cyclo-VEGI. Dunn-Bonferroni statistical analysis
was used to measure for significance between animal groups.
Results: Detailed analysis, at a single time point of 1 d post-QUIN injection, showed excitotoxin-injected
striatum to exhibit marked increases in microgliosis (ED1 marker), astrogliosis (GFAP marker) and VEGF
expression, compared with PBS injection. Single and double immunostaining demonstrated significant effects of
Cyclo-VEGI treatment of QUIN-injected striatum to inhibit microgliosis (by 38%), ED1/VEGF (by 42%) and VEGF
striatal immunoreactivity (by 43%); astrogliosis and GFAP/VEGF were not significantly altered with Cyclo-VEGI
treatment. Leakiness of BBB was indicated by infiltration of Evans blue dye and plasma protein fibrinogen into
QUIN-injected striatum with barrier permeability restored by 62% (Evans blue permeability) and 49% (fibrinogen
permeability) with Cyclo-VEGI application. QUIN-induced toxicity was demonstrated with loss of striatal neurons
(NeuN marker) and increased neuronal damage (Fluoro-Jade marker) with significant neuroprotection conferred
by Cyclo-VEGI treatment (33% increase in NeuN and 38% decrease in Fluoro-Jade).
Conclusion: An antagonist for VEGF receptor-mediated signaling, Cyclo-VEGI, has shown efficacy in a broad
spectrum of activity against striatal excitotoxic insult including inhibition of microgliosis, reduction in leakiness of
BBB and parenchymal infiltration of plasma fibrinogen and in conferring significant protection for striatal neurons.
Antagonism of VEGF-mediated activity, possibly targeting VEGF receptors on reactive microglia, is suggested as
a neuroprotective mechanism against inflammatory reactivity and a novel strategy to attenuate acute excitotoxic
damage.
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Excitotoxicity has been implicated as a contributing factor
in the pathogenesis of neurological disorders [1,2].
Although excitotoxic insult directly induces neuronal
damage through activation of glutamate subtype recep-
tors, results from several studies have suggested excito-
toxin-induced inflammatory processes could also
indirectly contribute to loss of neuron viability [3-7]. A
rapid enhancement of a spectrum of proinflammatory
mediators including cytokines, enzymes and free radicals
have been reported following excitotoxic brain insult [8-
11]. Resident glial cells, microglia and astrocytes, are a
likely source of the inflammatory factors [6,10,12,13].
Glial-derived factors can also cause rapid changes in vas-
cular processes and altered vasculature is a prominent fea-
ture of inflammatory responses in pathological
conditions including excitotoxicity [14]. Vascular
endothelial growth factor (VEGF) is a potent glial-derived
stimulator of vascular remodeling in various tissues with
both the VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1)-type
receptors expressed by endothelial cells. Evidence suggests
VEGFR-2 have critical functions in mediating angiogenic
[15] and neurogenic [16] activity. In contrast, the VEGFR-
1 subtype is predominantly expressed by microglia and
astrocytes and contributes to cellular chemotactic
responses [17,18]. VEGF-dependent signaling in brain has
been associated with both neuroprotection and neurotox-
icity [19-21] which could reflect differential effects of the
factor in binding to VEGF receptors on neurons, blood
vessels or glial cells.
The primary questions addressed in the present study
were the roles of microglial VEGF receptor and microglial
immunoreactivity in linking striatal excitotoxic insult
with vascular perturbations and neuronal damage. Initial
studies demonstrated a considerable extent of excitotoxic
lesion occurred at 1 d post-striatal injection of quinolinic
acid (QUIN) and detailed analysis was carried out at this
time point. Effects of the VEGF receptor antagonist Cyclo-
VEGI were determined on VEGF expression, gliosis, per-
meability of Evans blue dye and plasma protein fibrino-
gen through blood-brain barrier (BBB) and as a
pharmacological modulator of neuronal viability. The
overall results suggest microglial-derived VEGF as a critical
factor in mediating inflammatory reactivity and linking




Adult male Sprague-Dawley rats (Charles River Laborato-
ries, St. Constant, Quebec, Canada) weighting 250–300 g
were used in this study. The rats were housed in a temper-
ature and humidity controlled environment under a 12-hr
light-dark cycle with food and water available ad libitum.
All experimental procedures were approved by the Univer-
sity of British Columbia Animal Care Ethics Committee,
adhering to guidelines of the Canadian Council on Ani-
mal Care.
Administration of quinolinic acid (QUIN) and Cyclo-VEGI
Animals were anesthetized with intraperitoneal (i.p.)
injection of a mixture of ketamine hydrochloride (72 mg/
kg; Bimeda-MTC, Cambridge, Ontario, Canada) and xyla-
zine hydrochloride (9 mg/kg; Bayer Inc., Etobicoke,
Ontario, Canada) and then placed in a stereotaxic appara-
tus (David Kopf Instruments, Tujunga, CA). Intrastriatal
injection of quinolinic acid (QUIN) or PBS was per-
formed as previously described [6]. In brief, animals
received unilateral injection of 1 μl QUIN (60 nmol;
Sigma, St. Louis, MO) over 4 min using a 10 μl Hamilton
syringe fitted with a 26-gauge needle at the following
coordinate: AP: +1.0 mm, ML: -3.0 mm, DV: -5.0 mm,
from bregma [22]. The injection syringe was left in place
for an additional 4 min to allow the QUIN to diffuse from
the needle tip. After removing the needle, the skin was
sutured and the animals were allowed to recover and then
returned to their cages.
Cyclo-VEGI
The compound Cyclo-VEGI (Calbiochem, La Jolla, CA) is
a competitive antagonist acting at both the VEGF-2 (KDR)
and VEGF-1 (Flt-1) receptors [23]. The compound was
first dissolved in endotoxin-free water (Sigma) and further
diluted in PBS. Cyclo-VEGI (100 μM), in a volume of 4 μl,
was administered into right lateral ventricle (AP: -0.3 mm,
ML: -1.2 mm, DV: -4.0 mm from bregma) 30 min prior to
intrastriatal QUIN injection under the anesthesia. QUIN-
injected rats received lateral ventricular injection of PBS
vehicle. The dose and administration protocol of Cyclo-
VEGI followed published work [24,25].
Tissue preparation
Animals were deeply anesthetized with a mixture of keta-
mine and xylazine and then perfused transcardially with
heparinized cold saline followed by 4% paraformalde-
hyde in 0.1 M phosphate buffer (0.1 M PB, pH 7.4). The
brains were removed from the skull and postfixed in the
same fixative solution and then placed in 30% sucrose for
cryoprotection. The brains were then frozen in powdered
dry ice and stored at -70°C. Coronal brain sections (40
μm) were cut throughout the striatum on a cryostat and
the sections were stored in cryoprotectant solution.
Immunohistochemistry
Free-floating sections were processed for the immunohis-
tochemistry as described previously [6,7]. Briefly, endog-
enous peroxidase was quenched with 3% hydrogen
peroxide in 0.1 M PBS and sections were incubated inPage 2 of 10
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(NGS) and 0.2% Triton X-100 in 0.1 M PBS for 30 min.
The sections were then incubated at 4°C for 24 hr with the
following primary antibody against neuronal nuclei
(NeuN, 1:1000; Chemicon, Temecula, CA) or vascular
endothelial growth factor (VEGF, 1:200; Santa Cruz Bio-
technology, Santa Cruz, CA). Sections were incubated at
room temperature (RT) for 1 hr with biotinylated anti-
mouse or anti-rabbit IgG (1:1000; Vector, Burlingame,
CA), followed by an avidin-biotin-peroxidase complex
(ABC, 1:1000; Vector) for 1 hr. Reaction products were
visualized with 3,3'-diaminobenzidine (DAB, Sigma) and
hydrogen peroxide. Sections were washed in 0.1 M PB,
placed on Superfrost/Plus microscope slides (Fisher Scien-
tific; Pittsburgh, PA), dehydrated, and mounted in
Mountant (Fluka, Toronto, Canada). For immunofluores-
cence staining, sections were incubated with antibodies
against the following: ED1 (1:1000; Serotec, oxford, UK; a
marker for activated microglia/macrophages), glial fibril-
lary acidic protein (GFAP, 1:1000; Sigma; a marker for
astrocytes), rat endothelial cell antigen-1 (RECA-1, 1:500;
Serotec; a marker for endothelial cells), fibrinogen
(1:2000; DAKO, Carpinteria, CA) or NeuN (1:1000;
Chemicon) followed by Alexa Fluor-conjugated anti-
mouse or anti-rabbit IgG (1:500; Molecular Probes,
Eugene, OR) at RT for 2 hr in the dark. Omission of the
primary antibody was used as a negative control.
Double immunofluorescence staining
Double immunofluorescence staining was performed as
described previously [10]. In brief, sections were blocked
for 30 min with 10% NGS and incubated overnight at 4°C
with the following primary antibodies: anti-VEGF (1:200;
Santa Cruz Biotechnology) in combination with anti-ED1
(1:500; Serotec) or anti-GFAP (1:1000; Sigma). In another
experiment, sections were incubated with a mixture of
anti-VEGFR-1 (1:500; Santa Cruz Biotechnology; a marker
for VEGF receptor-1) and anti-ED1 (1:500; Serotec). Sec-
tions were then incubated in a mixture of Alexa Fluor-con-
jugated 488 anti-rabbit IgG (1:500; Molecular Probes)
and Alexa Fluor-conjugated 594 anti-mouse IgG (1:500;
Molecular Probes) at RT for 2 hr in the dark.
Image analysis
The five matched striatal sections (spaced 200 μm apart)
from each animal were used in the analysis. These sections
were representative of QUIN striatal injury as determined
by ED1 (microglia), GFAP (astrocytes), and NeuN (neu-
rons) immunohistochemistry [6]. All images were exam-
ined under a Zeiss Axioplan 2 fluorescent microscope
(Zeiss, Jena, Germany) using a DVC camera (Diagnostic
Instruments, Sterling Heights, MI, USA) and analyses were
performed with Northern Eclipse software (Empix Imag-
ing, Mississauga, ON, Canada). In each section, four non-
overlapped fields were randomly selected at a final mag-
nification of 400×. All quantitative analyses were carried
out in a blinded manner. The density of ED1, GFAP, and
NeuN immunoreactive cells in the striatum was evaluated
by counting of immunoreactive cells and expressed as the
number of cells/mm2. Fluoro-Jade B stained sections were
visualized under a fluorescence microscope using a fluo-
resceine (FITC) filter and Fluoro-Jade B fluorescent cells
were quantified and expressed as cells/mm2. Glial expres-
sion of VEGF was measured by counting the number
(cells/mm2) of double labeled ED1 and GFAP labeled for
VEGF. For quantification of VEGF or fibrinogen immuno-
histochemical staining, percentage of total area exhibiting
positive immunoreactivity was measured as described
previously [26].
Measurement of blood-brain barrier permeability
We used two approaches to examine integrity of blood-
brain barrier (BBB). One method measures extravasation
of the plasma protein fibrinogen into rat striatum. Stand-
ard immunohistochemical staining used antibody to
fibrinogen (see above) to quantify extents of area density
of striatal fibrinogen with the different animal treatments.
A second method determined infiltration of Evans blue
dye through a leaky BBB and followed published proce-
dures [26,27]. Briefly, Evans blue dye (2%, Sigma) was
administered by i.p. injection and animals sacrificed at 1
hr after the injection of the solution. Evans blue dye leak-
age into brain tissue was visualized on five striatal brain
sections (spaced 200 μm apart) under a fluorescent micro-
scope to determine fluorescent intensity [26].
Analysis for neuronal viability
Striatal neuronal damage was assessed by both immuno-
histochemical staining for neurons (use of NeuN as a
marker, see above) and Fluoro-Jade B staining. In the
former case, NeuN staining measured numbers of striatal
neurons with the different animal treatments. Fluoro-Jade
B staining, a marker for degenerating neurons, was used
following published protocols [6,28]. In brief, striatal sec-
tions were mounted on coated glass slides and incubated
in 0.06% potassium permanganate. The slides were then
incubated in 0.001% Fluoro-Jade B (Histo-Chem, Jeffer-
son, AR) for 20 min and washed in distilled water.
Statistical analysis
All data are expressed as means ± SEM. Statistical signifi-
cance of differences for group comparisons was assessed
by analysis of variance followed by the Dunn-Bonferroni
test. Significance was set at p < 0.05.
Results
Time dependent changes of gliosis and effects of the VEGF 
antagonist Cyclo-VEGI in QUIN-injected rat striatum
Initial experiments were designed to assess time-depend-
ent changes in microgliosis and astrogliosis induced byPage 3 of 10
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Time-dependent gliosis and effects of Cyclo-VEGI on microgliosis, astrogliosis and VEGF expression at 1 d post QUIN-intras-triatal injectionF gure 1
Time-dependent gliosis and effects of Cyclo-VEGI on microgliosis, astrogliosis and VEGF expression at 1 d 
post QUIN-intrastriatal injection. (A) Representative staining for microglia (ED1 marker) and astrocytes (GFAP marker) 
at 6 hr, 1 d and 7 d QUIN-injection; typical marker immunoreactivities (ir) for control PBS (7 d injection) are also shown. Scale 
bar represents 150 μm. (B) Photomicrographs of immunofluorescence staining for different injection protocols (1 d intra-stri-
atal injection). Typical patterns of staining are shown for ED1 ir microglia (upper panels), GFAP ir astrocytes (middle panels), 
and VEGF expression (lower panels). Scale bar represents 60 μm for ED1 panel and 300 μm for VEGF panel. The insets in 
VEGF panels show cell-associated VEGF; scale bar = 25 μm. (C) Bar graphs for ED1 (upper), GFAP (middle) and VEGF (lower) 
ir. Data are mean ± SEM (n = 5 animals/group). *p < 0.05 compared with PBS-injected group. #p < 0.05 compared with QUIN-
injected group.
Journal of Neuroinflammation 2008, 5:18 http://www.jneuroinflammation.com/content/5/1/18striatal injection of QUIN. Representative staining shows
microglial and astrocytic immunoreactivities (ir, markers
ED1 and GFAP, respectively) for QUIN injections of 6 hr,
1 d and 7 d and also 7 d PBS control (Fig. 1A). Both ED1
and GFAP ir were increased with QUIN stimulation from
6 hr to 1 d, however, both markers demonstrated no addi-
tional increases for the longest duration of QUIN injec-
tion at 7 d. At this time, PBS injected striatum showed low
levels of microgliosis and astrogliosis. Although data were
not quantified, the results suggested 1 d QUIN injection
as a time point for detailed analysis of gliosis and putative
VEGF-dependent activity in excitotoxin-injected rat brain.
We next examined effects of the VEGF antagonist, Cyclo-
VEGI (intraventricle administration at 100 μM) on extents
of gliosis and VEGF ir with intrastriatal QUIN injection (1
d). Marked increases in both ED1 and GFAP ir were evi-
dent following QUIN compared with PBS control (upper
and middle left panels, Fig. 1B). Representative immunos-
taining showed microgliosis, but not astrogliosis, was
attenuated with Cyclo-VEGI treatment in QUIN-injected
striatum with the VEGF antagonist alone showing gliosis
ir similar to control (upper and middle right panels, Fig.
1B). Quantification of data is presented in Fig. 1C (n = 5
animals/group), with Cyclo-VEGI treatment exhibiting a
significant reduction in ED1 ir (by 38%) when injected
with QUIN compared with QUIN stimulation alone (Fig.
1C, upper bar graph). Although Cyclo-VEGI decreased
GFAP ir by 13% in QUIN-injected striatum, the change
was not significant (Fig. 1C, middle bar graph). Applica-
tion of Cyclo-VEGI alone was associated with similar pat-
terns of gliosis as measured with PBS control striatal
injection.
Levels of striatal VEGF were considerably elevated in
QUIN-injected rat striatum compared with PBS injection
(Fig. 1B, lower left panels). Cyclo-VEGI was effective in
diminishing VEGF ir when applied in QUIN-injected
striatum and showed no induced VEGF ir when applied
alone (Fig. 1B, lower right panels). Higher magnification
insets shows typical VEGF staining in association with
cells in QUIN and QUIN + Cyclo-VEGI injected striatum.
VEGF ir cells exhibited a microglial-like cellular morphol-
ogy particularly evident with QUIN injection; this point
was investigated using double staining (see below). Over-
all (n = 5 animals/group), VEGF ir was increased 8-fold
with QUIN, relative to PBS, injection (Fig. 1C, lower bar
graph). Cyclo-VEGI exhibited a significant reduction in
VEGF ir (by 43%) in QUIN-injected striatum. Levels of
striatal VEGF were similar with injection of PBS or Cyclo-
VEGI applied alone.
Effects of Cyclo-VEGI on glial-cell associated VEGF
As noted, QUIN-injected rat striatum demonstrated a pat-
tern of VEGF association with glia with cells exhibiting a
roundish appearance indicative of activated microglia
(insets, lower panel, Fig. 1B). In order to address this
point, double immunohistochemical staining was used to
examine VEGF localization with ED1 (+)ve microglia or
GFAP (+)ve astrocytes. Representative double staining
shows ED1/VEGF ir with the different treatments in Fig.
2A (upper row). Considerable extents of VEGF ir were
associated with microglia in QUIN-injected striatum.
Double staining of ED1/VEGF was diminished with
Cyclo-VEGI treatment of QUIN-injected animals with the
VEGF receptor antagonist alone showing a similar double
staining pattern as for PBS control. As shown in Fig. 2B,
ED-1 (+)ve microglia stain positively for VEGF receptor-1
(VEGFR-1) in QUIN-injected brain. Limited analysis of
brain tissue estimated in excess of 90% of microglia
expressed the VEGFR-1 marker. Interestingly, microglia
demonstrated a highly reactive morphology of rounded
cell bodies and retracted processes with excitotoxic insult.
No VEGFR-1 immunoreactivity was observed with GFAP
(+)ve astrocytes (data not shown). Representative GFAP/
VEGF staining patterns for the different animal groups are
shown in Fig. 2A (lower row). QUIN-injected brain
showed evidence for VEGF localization with astrocytes
which was reduced with Cyclo-VEGI treatment of excito-
toxin-injected brain. Cyclo-VEGI alone demonstrated a
pattern of GFAP/VEGF similar to PBS control.
Overall (n = 5 animals/group), Cyclo-VEGI significantly
inhibited ED1/VEGF ir by 42% (Fig. 2C, left bar graph). A
comparison of single ED1 staining (Fig. 1C, upper bar
graph) with double ED1/VEGF staining (Fig. 2C, left bar
graph) suggests about 40% of total microglia were associ-
ated with VEGF in QUIN-injected striatum. Quantifica-
tion of data (Fig. 2C, right bar graph) showed a 31%
reduction in GFAP/VEGF ir with Cyclo-VEGI application
to QUIN-stimulated striatum, however, this decrease did
not reach significance (n = 5 animals/group). Cyclo-VEGI
applied alone showed low levels of GFAP/VEGF ir. A com-
parison of GFAP single staining (Fig. 1C, middle bar
graph) with GFAP/VEGF double staining (Fig. 2C, right
bar graph) would suggest that less than 10% of astrocytes
were associated with VEGF.
Effects of Cyclo-VEGI on BBB permeability
We next designed experiments to test permeability of BBB,
in the absence and presence of Cyclo-VEGI administra-
tion, in QUIN-injected striatum. Two different
approaches were used; infiltration of Evans blue dye and
extravasation of the plasma protein, fibrinogen. In the lat-
ter case, we also analyzed for fibrinogen ir in conjunction
with endothelial cells using the endothelial specific cell
marker RECA-1 (rat endothelial cell antigen). Typical
Evans blue dye fluorescence for the different injections are
presented in Fig. 3A (upper panels) and show considera-
ble dye present in QUIN-injected brain but absent in PBSPage 5 of 10
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attenuated with Cyclo-VEGI administration in QUIN-
injected animals and was absent with Cyclo-VEGI treat-
ment alone. Overall (n = 5 animals/group), Cyclo-VEGI
was effective in reducing Evans blue fluorescence (by
62%) when applied in excitotoxin-injected animals (Fig.
3B). Low Evans blue fluorescence was measured in PBS
control or with Cyclo-VEGI application alone.
Representative staining for fibrinogen are shown in Fig.
3A (lower panels). No fibrinogen ir was observed with
PBS injection but high levels of striatal plasma protein
were evident following QUIN injection. Cyclo-VEGI treat-
ment was effective in attenuating fibrinogen ir in excito-
toxin stimulated brain with no effect when applied alone.
In total (n = 5 animals/group), Cyclo-VEGI demonstrated
significant effects to attenuate levels of fibrinogen ir (by
49%) when administered with QUIN. Little or no fibrin-
ogen ir accompanied Cyclo-VEGI administration alone.
Typical patterns of RECA-1 ir are presented in insets of the
fibrinogen staining (Fig. 3A, lower panels). The results
indicate viable endothelial cells in PBS-injected striatum
but fragmented cells in excitotoxin-injected striatum. Rep-
resentative RECA-1 ir with Cyclo-VEGI application with
QUIN or applied alone showed similar RECA-1 staining
as for control. These data suggest abnormalities in
endothelial cell structure are associated with QUIN-stri-
Effects of Cyclo-VEGI on VEGF association with glial cellsFigure 2
Effects of Cyclo-VEGI on VEGF association with glial cells. (A) Double staining for ED1/VEGF (upper panels) and 
GFAP/VEGF (lower panels) after 1 d injections of PBS (left panel), QUIN (left middle panel), QUIN with Cyclo-VEGI (right 
middle panel) and Cyclo-VEGI (right panel). Scale bar = 50 μm. (B) Representative examples of merged staining for VEGFR-1 
with ED1 (+)ve microglia. Scale bar = 15 μm. (C) Quantitative analysis for the area density of ED1/VEGF (left bar graph) and 
GFAP/VEGF (right bar graph). Data are mean ± SEM (n = 5 animals/group). *P < 0.05 compared with PBS-injected group. #P < 
0.05 compared with QUIN-injected group.Page 6 of 10
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Cyclo-VEGI treatment.
Effects of Cyclo-VEGI on neuronal viability
An important end-point of this study was to examine if
antagonism of VEGF receptor expression was neuropro-
tective in excitotoxin-injected brain. This question was
assessed in two ways; measurement of numbers of viable
striatal neurons using NeuN as a marker and determina-
tion of numbers of damaged neurons using Fluoro-Jade B
as a marker. We first examined time-dependence of neu-
ronal viability (NeuN marker) using the same time points
as for gliosis (Fig. 1). Representative NeuN staining (Fig.
4A) shows a marked loss of striatal neurons at 1 and 7 d
post-QUIN injection compared with the early time point
of QUIN injection (6 hr) or after long-term PBS injection
(7 d).
Representative NeuN ir shows a considerable attenuation
in numbers of neurons following QUIN injection com-
pared with PBS control (Fig. 4B, upper panels). Some
recovery in numbers of striatal neurons was evident with
Cyclo-VEGI treatment with excitotoxin. Cyclo-VEGI alone
showed similar NeuN ir as for PBS control. Quantification
of data is presented in Fig. 4C (upper bar graph) with
numbers of neurons reduced by 39% (QUIN vs PBS; n =
5 animals/group). Cyclo-VEGI significantly increased
numbers of NeuN (+)ve striatal neurons by 33% (QUIN +
Cyclo-VEGI vs QUIN). Numbers of neurons with Cyclo-
VEGI alone were similar to PBS control.
Representative Fluoro-Jade B staining is shown (Fig. 4B,
lower panels). Little or no Fluoro-Jade B (+)ve cells were
evident in control or with Cyclo-VEGI administered
alone. Marked striatal damage was observed following
QUIN injection with Cyclo-VEGI effective in diminishing
the marker of neuronal damage when added with excito-
toxin. Overall (n = 5 animals/group), Cyclo-VEGI reduced
Fluoro-Jade B (+)ve cells by 38% representing a significant
effect to protect striatal neurons from damage (Fig. 4C,
lower bar graph).
Discussion
This study is the first report that excitotoxin-induced stri-
atal lesion induces VEGF-mediated signaling as part of an
overall inflammatory response. Evidence is provided that
pharmacological inhibition of VEGF receptors leads to
reduced microgliosis and an increased integrity of BBB
and that modulation of these processes link neuronal via-
bility with excitotoxic insult. As discussed below, the
results implicate activation of microglial cells as a mecha-
nism for induction of striatal neurodegeneration. Further-
more, VEGF-dependent signaling pathways are identified
as candidates for pharmacological modulation to reduce
Effects of Cyclo-VEGI on intactness of BBBFigure 3
Effects of Cyclo-VEGI on intactness of BBB. (A) Photomicrographs of representative fluorescence images of Evans blue 
dye (upper panels) and fibrinogen (lower panels) with the different striatal injections (1 d post-injection): PBS (left panel), 
QUIN-injection (left middle panel), QUIN-injected rats with Cyclo-VEGI (right middle panel) and Cyclo-VEGI alone (right 
panel) treatment. Scale bar represents 500 μm. The insets in fibrinogen panels show typical RECA-1 ir; scale bars represent 
150 μm for fibrinogen panel and 100 μm for RECA-1 panel. (B) Quantitative analysis of Evans blue dye (upper graph) and fibrin-
ogen (lower graph) fluorescence intensity for the different procedures. Data are mean ± SEM (n = 5 animals/group). *P < 0.05 
vs. PBS-injected group. #P < 0.05 vs. QUIN-injected group.Page 7 of 10
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under excitotoxic conditions.
Cyclo-VEGI showed a wide spectrum of effects in QUIN-
injected brain including inhibition of multiple processes
including VEGF expression, gliosis, impairment and leak-
iness of BBB and neuronal damage. This compound, like
other VEGF receptor antagonists, binds to both VEGF1
(Flt-1) and VEGF2 (Flk-1)-type receptors [23,29] likely
reflecting the similar tyrosine kinase structures of the two
receptors. The single staining data (Fig. 1B) and double
staining results (Fig. 2A) suggests that resident microglia,
or macrophage-like immune responding cells, are the pri-
mary cells expressing VEGF and which are targeted by
Cyclo-VEGI. Furthermore, the present data suggests
microglia express VEGFR1 consistent with results from
previous studies [17,18]. In this case Cyclo-VEGI binding
to VEGFR-1 in activated microglia could inhibit cellular
reactivity and VEGF production leading to a reduced vas-
cular permeability for fibrinogen infiltration into stria-
tum. A lower extravasation of fibrinogen would, in a
positive feedback manner, attenuate microglial activation
and amplification of inflammatory responses. This auto-
crine scheme would be consistent with the finding of
altered RECA-1 staining patterns (insets, Fig. 3) indicating
abnormalities in endothelial cells in QUIN-injected stria-
tum with some recovery provided by Cyclo-VEGI treat-
ment. However, protection against endothelial cell
Effects of Cyclo-VEGI on viability of striatal neuronsFigure 4
Effects of Cyclo-VEGI on viability of striatal neurons. (A) Time-dependent changes in numbers of NeuN (+)ve neurons 
with QUIN injection (6 hr, 1 and 7 d) and PBS injection at 7 d. Scale bar = 100 μm. (B) Photomicrographs of NeuN (+)ve neu-
rons (upper row) and Fluoro-Jade B (+)ve degenerating neurons (lower row) in striatum from PBS (left panels), QUIN-injected 
(left middle panels), QUIN-injected rats with Cyclo-VEGI treatment (right middle panels), and Cyclo-VEGI alone (right panels) 
at 1 day post-injection. Scale bar represents 60 μm. (C) Quantification of the number of NeuN (+)ve neurons (upper bar 
graph) and Fluoro-Jade B (+)ve degenerating neurons (lower bar graph) in striatum for the four procedures. FJ; Fluoro-Jade B. 
Data are mean ± SEM (n = 5 animals/group). *p < 0.05 compared with PBS. #p < 0.05 compared with QUIN-injected rats.Page 8 of 10
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Cyclo-VEGI binding to VEGF receptors on endothelial
cells. In this case, paracrine effects of microglial VEGF act-
ing on endothelium would be diminished with effects of
the VEGF antagonist directed at vasculature. At present,
the relative extents of microglial autocrine and paracrine
(vascular actions) in excitotoxin-injected brain are not
known.
The present results indicate reactive microglia could serve
as a link between excitotoxic insult and striatal neurode-
generation. In this event, damage to striatal neurons could
result from activated microglial secretion of an assem-
blage of inflammatory mediators. The specific nature of
mediators was not addressed but likely candidates would
include proinflammatory cytokines and reactive oxygen
and nitrogen species. It can be speculated that QUIN-
injection could have dual effects to both increase micro-
glial secretion of VEGF and expression of VEGFR-1 which
would provide both a chemotactic cellular stimulus and
also amplify inflammatory responses. However, our
results do not preclude QUIN injection causing a direct
and rapid excitotoxic striatal injury contributing to overall
neuronal damage. Interestingly, such a process could also
initiate a microglial chemotactic response mediated by
factors such as ATP released from damaged neurons
[30,31]. Thus, Cyclo-VEGI could still be effective in inhib-
iting microglial mobility and chemotaxis with direct exci-
totoxicity induced by striatal injection of QUIN. An
interesting possibility for future study would be to inves-
tigate inflammatory responses to excitotoxic insult in vivo
using a soluble protein treatment to sequester VEGF
[32,33].
It is important to note that the findings of deleterious
VEGF effects in QUIN-injected intact animals are not
demonstrated in vitro where VEGF is reported to enhance
viability of cultured neurons against excitotoxic insult
[34,35]. Neurons can express both VEGFR-1 and VEGFR-
2 with evidence suggesting that VEGF binding to the latter
receptor confers neuroprotection [34]. The underlying
reasons for the differential VEGF effects are not known,
however, one possibility is that in the absence of glial
stimulation, binding of VEGF to neurons is neurotrophic.
Our findings in intact animals suggest the utility of future
in vitro experiments to examine effects of VEGF applied in
co-cultures of neurons and glia which are exposed to exci-
totoxic conditions.
Conclusion
Excitotoxicity is manifest under conditions of elevated
glutamate and thus could contribute to a spectrum of
pathological conditions including ones in neurodegener-
ative diseases. However, VEGF may have multifactorial
functional roles in different diseases such as demonstrated
with beneficial effects of VEGF treatment in amyotrophic
lateral sclerosis [16] and detrimental effects in multiple
sclerosis [36] or where excitotoxic conditions prevail.
Overall, the present results are consistent with an acute
excitotoxic insult inducing extensive inflammatory reac-
tivity which includes vascular leakiness and diminished
neuronal viability. The findings from this work suggest
that in addition to using antagonists for glutamate sub-
type receptors, amelioration of brain excitotoxicity could
be derived from inhibition of VEGFR-1-dependent micro-
glial inflammatory signaling pathways.
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